Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew Ahmann(Oregon Health & Science University), Vanita R. Aroda(Brigham and Women's Hospital), G. Charpentier(Centre Hospitalier Sud Francilien), Ildiko Lingvay(Southwestern Medical Center), Elena Henkel(GWT-TUD (Germany)), Francesco Dotta(University of Siena), Matthew Capehorn(Rotherham General Hospital), Miriam Annett(Novo Nordisk (United States)), Anders G. Holst(Novo Nordisk (Denmark))
Cited by 574
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetes Care|2022|1.9k
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
|Diabetologia|2022|986
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|850